128 related articles for article (PubMed ID: 36871476)
1. Shenlingcao oral liquid for patients with non-small cell lung cancer receiving adjuvant chemotherapy after radical resection: A multicenter randomized controlled trial.
Liu Y; Luo X; Liu J; Ma Y; Tan J; Wang W; Hu J; Fu X; Xu L; Yu F; Xu S; Ma H; Yu X; You Q; Wang Z; Li L; Zhang X; Sun X
Phytomedicine; 2023 May; 113():154723. PubMed ID: 36871476
[TBL] [Abstract][Full Text] [Related]
2. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
Yao J; Jiao L; Yao Y; Lu Y; Shi J; Li J; Chen P; Xu L; Gong Y
Trials; 2020 Apr; 21(1):309. PubMed ID: 32245480
[TBL] [Abstract][Full Text] [Related]
3. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Bezjak A; Lee CW; Ding K; Brundage M; Winton T; Graham B; Whitehead M; Johnson DH; Livingston RB; Seymour L; Shepherd FA
J Clin Oncol; 2008 Nov; 26(31):5052-9. PubMed ID: 18809617
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.
Xiao Z; Chen Z; Han R; Lu L; Li Z; Lin J; Hu L; Huang X; Lin L
Medicine (Baltimore); 2021 May; 100(18):e25690. PubMed ID: 33950949
[TBL] [Abstract][Full Text] [Related]
6. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
Gao R; Zhang Y; Hou W; Li J; Zhu G; Zhang X; Xu B; Wu Z; Wang H
Trials; 2021 Mar; 22(1):214. PubMed ID: 33731199
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of Radical Resected NSCLC by Chinese Medicine Combined with Adjuvant Chemother- apy: a Clinical Study].
Hou WX; Li HG; Chen ZW; Zhu LH; Zhao LH; Tian JH; Xu WJ; Zhou L; Yao YL
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jun; 35(6):648-53. PubMed ID: 26242112
[TBL] [Abstract][Full Text] [Related]
8. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
12. Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.
Lu S; Yu Y; Barnes G; Qiu X; Bao Y; Tang B
Cancer J; 2022 Mar-Apr 01; 28(2):96-104. PubMed ID: 35333492
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
14. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
Tsakiridis T; Pond GR; Wright J; Ellis PM; Ahmed N; Abdulkarim B; Roa W; Robinson A; Swaminath A; Okawara G; Wierzbicki M; Valdes M; Levine M
JAMA Oncol; 2021 Sep; 7(9):1333-1341. PubMed ID: 34323924
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled pilot trial of "Feiji Recipe" on quality of life of non-small cell lung cancer patients.
Tian JH; Liu LS; Shi ZM; Zhou ZY; Wang L
Am J Chin Med; 2010; 38(1):15-25. PubMed ID: 20128041
[TBL] [Abstract][Full Text] [Related]
17. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
Xu L; Li H; Xu Z; Wang Z; Liu L; Tian J; Sun J; Zhou L; Yao Y; Jiao L; Su W; Guo H; Chen P; Liu J
BMC Complement Altern Med; 2012 Aug; 12():112. PubMed ID: 22853619
[TBL] [Abstract][Full Text] [Related]
18. Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Zeng J; Mao WM; Chen QX; Luo TB; Wu YL; Zhou Q; Yang XN; Yan HH; Zhong WZ; Wang Q; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT
Lung Cancer; 2020 Dec; 150():164-171. PubMed ID: 33186858
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
